To include your compound in the COVID-19 Resource Center, submit it here.

Assembly reports Phase Ib data for HBV candidate

Assembly Biosciences Inc. (NASDAQ:ASMB) reported data from the Phase Ib ABI-H0731-101b trial in treatment-naïve patients with chronic HBV infection showing that ABI-H0731 was generally well tolerated with no serious adverse events

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers